HomeCricket

Cricket

Jamaica Paper - Latest News and In-depth Analysis
Cricket

HONOR Underscores Commitment to Open Collaboration at MWC Barcelona 2025

In two engaging discussions,HONOR sheds light on the envisioned future that the HONOR ALPHA PLAN will achieve

Mar 5, 2025
Cricket

Callio Therapeutics Launches with US$187 Million Series A to Advance Multi-Payload Antibody-Drug Conjugate Platform Through Clinical Proof-of-Concept

Frazier Life Sciences launches Callio Therapeutics based on multi-payload antibody-drug conjugate technology and programs exclusively in-licensed from Singapore-based Hummingbird Bioscience

Mar 5, 2025
Cricket

ZekoAI: Powering Private, Decentralized, and Automated Artificial Intelligence Workflows

SAN FRANCISCO,March 3,2025--The convergence of artificial intelligence,zero-knowledge,and decentralized finance represents a transformative frontier in blockchain technology. By combining Zeko\'s zer

Mar 5, 2025
Cricket

CStone Announces First Patient Dosed in Global Multicenter Phase I Clinical Trial of CS2009, a PD-1/VEGF/CTLA-4 Trispecific Antibody

SUZHOU,China,March 4,2025--CStone Pharmaceuticals ("CStone",HKEX: 2616),an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies,today

Mar 5, 2025
Cricket

ITU and Huawei Jointly Release the White Paper on Lithium Batteries for Telecom Sites

BARCELONA,Spain,March 4,2025-- Huawei Global Digital Power Summit was held at MWC 2025 with the theme of "AI Powering a Greener ICT." Operators,leading enterprises,industry leaders,and indus

Mar 5, 2025
Cricket

Celltrion receives U.S. FDA approval for STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) biosimilars referencing PROLIA® and XGEVA®

STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) are approved by FDA for all indications of reference products PROLIA® (denosumab) and XGEVA® (denosumab) respectively[1],[2]

Mar 5, 2025
1 ... 37 38 39 40 41 42 43 ... 104